Skip to main content
AUTL logo

Autolus Therapeutics plc (AUTL) Stock Price & Analysis

Autolus Therapeutics plc (AUTL) — MoonshotScore 15/100 (Weak band), calculated Nov 18, 2026. Price $0.9073 (-7.38%), as of the Nov 20, 2026 trading session; market cap $242M.

Educational signal · not a buy or sell recommendation · How to read this

$0.9073 −$0.0723 (-7.38%) Market Cap $242M

Autolus Therapeutics plc · AUTL · NASDAQ

Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in T-cell-based immunotherapies for various cancers.

Price as of Nov 20, 2026

Key Statistics

15 of 100

MoonshotScore v2 · Autolus Therapeutics (AUTL)

Weak
Business Quality Poor (16)
Financial Safety Strained (28)
Valuation Bubble (10)
Growth Durability Compounding (81)
Momentum Slipping (35)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Only growth holds up — quality and the balance sheet are near the sector floor; far more to fix here than to build on, and it’s expensive on top. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Compounding; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • EPS beat 0 of the last 3 reports
  • Altman Z -4.21 · Piotroski F 3

Holding back: weak fundamentals, balance-sheet strain, a rich price

Helping: durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for AUTL (53 recorded, newest six shown)
RecordedScoreBand
14Weak
14Weak
14Weak
15Weak
15Weak
15Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.9073
Change on the day-7.38%
52-week range$0.9073 – $2.58
Market capitalisation$242M—
Price / earnings (trailing)-1.81
Shares traded on the day3.90M

Price & events

Other perspectives

Council score for Autolus Therapeutics (AUTL): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Negative
Growth Durability Strong
Momentum Weak

Legends Council

5 lenses, 5 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Autolus Therapeutics (AUTL), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Autolus Therapeutics plc (AUTL) is listed on NASDAQ. It employs 752 people and is led by Christian Martin Itin. The market values it at $242M.

2 · Latest results

What do the latest results show for Autolus Therapeutics (AUTL)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 3 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$21M-$79M-$0.30 (diluted)
Q4 FY2025$24M-$90M—
Q1 FY2026$26M-$72M-$0.27 (diluted)
Q2 FY2026$46M-$39M-$0.15 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Autolus Therapeutics (AUTL)?

Short answer

The MoonshotScore pillars rate durable growth as strengths. What is holding it back is weak fundamentals, balance-sheet strain, a rich price. The distress and quality screens read Altman Z -4.21 · Piotroski F 3. Trailing ratios: ROA -22.5% · current ratio 3.72.

Data-derived red flags

  • Listing risk — at $0.9073 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -4.21 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Autolus Therapeutics compare with its peers?

Short answer

Autolus Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$86.6M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.43 Nov 20, 2026$1.02B64 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Autolus Therapeutics (AUTL) — this page$0.9073$242M15

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held AUTL in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported AUTL in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Autolus Therapeutics (AUTL)?

Read these with our analysis →

Investor Questions: AUTL Stock

These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.

What does the MoonshotScore mean for AUTL?

AUTL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is AUTL a good stock to buy?

Stock Expert AI does not rate AUTL buy, sell or hold. Autolus Therapeutics plc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the AUTL stock price today?

The last price recorded for Autolus Therapeutics plc (AUTL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key factors to evaluate for AUTL?

Autolus Therapeutics plc (AUTL) holds a MoonshotScore in the low range. Not financial advice.

How frequently does AUTL data refresh on this page?

AUTL's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven AUTL's recent stock price performance?

Autolus Therapeutics plc (AUTL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust clinical pipeline with multiple T-cell immunotherapy candidates targeting various cancers. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider AUTL overvalued or undervalued right now?

Autolus Therapeutics plc (AUTL) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research AUTL before investing?

Before investing in Autolus Therapeutics plc (AUTL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding AUTL to a portfolio?

Key strength of Autolus Therapeutics plc (AUTL): Robust clinical pipeline with multiple T-cell immunotherapy candidates targeting various cancers. Weigh rewards against risks and diversify. Not financial advice.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.